Key facts
- GexVal’s last known valuation is $16.4M (Jan 2025).
- It has raised $15.4M; the latest was Later Stage VC ($5.5M) in Jan 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, UTC Investment, Takeda Ventures, Alfresa Holdings — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for GexVal
- ·The full record, as it builds
Funding rounds
No funding rounds for GexVal are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GexVal
Developer of a drug designed to focus on orphan and intractable diseases. The company develops compounds for the treatment of rare diseases in the psychiatry and neurology areas and for pulmonary arterial hypertension, enabling physicians to treat rare diseases and patients with rare and incurable diseases with innovative, cost-effective treatment options.
- Sector
- Healthcare
- HQ
- Fujisawa, Japan
- Founded
- 2018
- Employees
- 12
- Website
- gexval.com/
- Ownership
- Privately Held (backing)
GexVal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GexVal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GexVal in its N-PORT filings yet. We sweep new filings monthly.